MY188689A - Gene therapy composition - Google Patents

Gene therapy composition

Info

Publication number
MY188689A
MY188689A MYPI2018701967A MYPI2018701967A MY188689A MY 188689 A MY188689 A MY 188689A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY 188689 A MY188689 A MY 188689A
Authority
MY
Malaysia
Prior art keywords
genes
gene therapy
apoptosis
therapy composition
inducing
Prior art date
Application number
MYPI2018701967A
Inventor
Tetsuyuki Hirahata
Original Assignee
Tetsuyuki Hirahata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetsuyuki Hirahata filed Critical Tetsuyuki Hirahata
Publication of MY188689A publication Critical patent/MY188689A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Problem: To provide a gene therapy composition, which gene therapy composition promotes cancer cell apoptosis by delivering apoptosis-inducing genes comprising a combination of multiple genes into cancer cells, and to a liposome vector for transferring the gene therapy composition to cancer cells and a method of preparing the liposome vector. Solution: A gene therapy composition comprising a gene therapy composition for preventing and/or treating cancer whose anti-tumor genes are apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. composition for preventing and/or treating cancer whose anti-tumor genesare apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. (Figure 1)
MYPI2018701967A 2015-10-23 2015-10-23 Gene therapy composition MY188689A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/005342 WO2017068614A1 (en) 2015-10-23 2015-10-23 Gene therapy composition

Publications (1)

Publication Number Publication Date
MY188689A true MY188689A (en) 2021-12-23

Family

ID=58557009

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018701967A MY188689A (en) 2015-10-23 2015-10-23 Gene therapy composition

Country Status (4)

Country Link
JP (1) JP6837984B2 (en)
MY (1) MY188689A (en)
SG (1) SG11201803940PA (en)
WO (1) WO2017068614A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020050665A1 (en) 2018-09-05 2020-03-12 엘지전자 주식회사 Method for encoding/decoding video signal, and apparatus therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506651A (en) * 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド Multi-gene vector

Also Published As

Publication number Publication date
SG11201803940PA (en) 2018-06-28
JPWO2017068614A1 (en) 2018-08-09
WO2017068614A1 (en) 2017-04-27
JP6837984B2 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
HK1252351A1 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3411079A4 (en) Engineered mammalian cells for cancer therapy
IL260959A (en) Gene therapy for treating mucopolysaccharidosis type i
GB2557123A (en) Modified cells and methods of therapy
EP3364969A4 (en) Methods of preparing t cells for t cell therapy
EP3370743A4 (en) Methods for preparing cells for adoptive t cell therapy
MX2018001776A (en) Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation.
MX2018004263A (en) Multiplexed genome editing.
MX2018005377A (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.
PH12017501999A1 (en) K-ras modulators
EP3260539A4 (en) Method for transferring cas9 mrna into mammalian fertilized egg by electroporation
WO2016012544A3 (en) Enhanced reprogramming to ips cells
MX2022012013A (en) Compositions and methods for tumor transduction.
MX368442B (en) Fusion protein inhibiting angiogenesis or growth and use thereof.
EP3207377A4 (en) Circulating tumor cell diagnostics for therapy targeting pd-l1
EP3554557A4 (en) Methods of treating cells containing fusion genes by genomic targeting
MX2021014663A (en) Compound targeting il-23a and tnf-alpha and uses thereof.
MX2019010039A (en) Compositions and methods for tumor transduction.
IL273427A (en) Gene therapy for treating mucopolysaccharidosis type ii
EP3717653A4 (en) Gene therapy for mucopolysaccharidosis iiia
EP3998341A3 (en) Adenoviral vectors
IL267057A (en) Gene therapy for mucopolysaccharidosis, type i
NZ726050A (en) Modulators of androgen synthesis
WO2017091885A8 (en) Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
MX2014003094A (en) Methods of promoting differentiation.